Novavax's COVID-Flu Combo Shot Shows Strong Immune Response

Novavax NVAX announced positive initial results from a late-stage study of its COVID-19-influenza combination (CIC) vaccine candidate, showing robust immune responses in older adults across multiple flu strains and SARS-CoV-2, comparable to its Nuvaxovid and Sanofi's Fluzone HD. This announcement follows the recent FDA approval of Nuvaxovid with a narrower label and Sanofi's assumption of commercial responsibility for the vaccine under a multi-billion-dollar deal. Novavax is also exploring strategic collaborations to finance further development and potential commercialization of both candidates amidst competition from Pfizer and Moderna in the COVID/flu combination vaccine space.

Analysis

Novavax has reported encouraging, albeit preliminary, immunogenicity data from its late-stage study of COVID-19-influenza combination (CIC) and standalone influenza vaccine candidates in older adults, with responses showing robust immune responses across three flu strains (H1N1, H3N2, and B) and the SARS-CoV-2 strain, comparable to its approved Nuvaxovid and Sanofi's Fluzone HD. These findings, from a study not designed for statistical significance, are intended to guide a subsequent late-stage study aimed at potential regulatory submissions, aligning with Novavax's strategic shift to expand its pipeline and actively seek collaborations to finance further development and commercialization. This development follows the recent FDA approval of Nuvaxovid, which, despite a narrower-than-anticipated label (full approval for 65+, restricted for 12-64 with high-risk conditions), is now under Sanofi's commercial responsibility globally (excluding certain territories) through a multi-billion-dollar agreement, securing tiered royalties for Novavax. While Novavax's shares have underperformed the industry year-to-date, the progress in its combination vaccine program occurs as key competitors Pfizer and Moderna face their own developmental hurdles with similar mRNA-based candidates—Pfizer reporting a Phase III study miss and Moderna withdrawing an FDA filing—potentially offering Novavax a strategic window if its program advances successfully. Novavax currently carries a Zacks Rank #3 (Hold).

Key Decisions for Investors

• Investors should closely monitor Novavax's progress in initiating and executing the subsequent late-stage study for its CIC and flu vaccines, as well as any developments regarding strategic partnerships essential for funding and commercialization.
• Given the preliminary nature of the current positive data, the stock's recent underperformance, the narrower Nuvaxovid label, and reliance on Sanofi for Nuvaxovid revenue, a balanced view is warranted, weighing the pipeline potential against existing commercial realities, execution risks, and competitive pressures.
• Developments from competitors Pfizer and Moderna in the COVID-flu combination vaccine space, particularly their ability to overcome recent setbacks and their updated trial timelines, should be tracked as these will significantly influence the market dynamics and Novavax's competitive positioning.